Anders Dahlén, Ph.D.Associate Director, Oligo Chemistry Team at AstraZeneca
Anders Dahlén studied Chemistry at Gothenburg University (Sweden) where he finalized his MSc in 2000, and his PhD on organometallic synthetic chemistry in 2005. Anders was recruited into the chemistry section of Cardiovascular, Renal and Metabolic Diseases, AstraZeneca R&D, in 2005 and was initially working in small molecule discovery before he joined the New Modalities Chemistry Team in 2013. During his time at AstraZeneca, Anders has held roles as Senior Scientist, Associate Principal Scientist, New Modalities Chemist and Team Leader. The past 4 years, Anders has been leading the efforts of the New Modalities Chemistry Team in CVRM, including work on peptides, oligos, conjugates, lipids for LNPs, 5’-caps, PNAs and PROTACs. Anders is also involved in several academic collaborations within the framework of the FormulaEx and MMBio networks. Anders is currently Team Leader of the Oligo Chemistry Team within Discovery Sciences. In his spare time, Anders enjoys orienteering and spending time with his family.